Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling

Autor: Pekka Ellonen, Dorine Bellanger, Jing Tang, Bhagwan Yadav, Emma I. Andersson, J P Mpindi, Olli Dufva, Samuli Eldfors, Wei Ding, Katarzyna Tomska, Marc-Henri Stern, Tea Pemovska, Carlos Cuesta-Mateos, Anneli Lauhio, Henan Zhang, Satu Mustjoki, T H Brümmendorf, Krister Wennerberg, Steffen Koschmieder, Giuliano Crispatzu, Alexandra Schrader, Soili Kytölä, Shady Adnan-Awad, Leopold Sellner, Marco Herling, Edgar Faber, Olli Kallioniemi, Małgorzata Oleś, S. Pützer, Sofia Khan, Sonja Lagström, Liye He, Timo Siitonen, Eeva-Riitta Savolainen, Paavo Pietarinen, Simon Anders, Tero Aittokallio, Wolfgang Huber, Thorsten Zenz
Rok vydání: 2018
Předmět:
Male
0301 basic medicine
Cancer Research
Gene Expression
Drug resistance
Pharmacology
medicine.disease_cause
0302 clinical medicine
Molecular Targeted Therapy
Prolymphocytic leukemia
Oxazoles
media_common
Aged
80 and over
Mutation
Cell Cycle
Hematology
Middle Aged
3. Good health
STAT Transcription Factors
Phenotype
Oncology
030220 oncology & carcinogenesis
Female
Drug
media_common.quotation_subject
Antineoplastic Agents
Biology
03 medical and health sciences
Cell Line
Tumor
Biomarkers
Tumor
medicine
Humans
Protein Kinase Inhibitors
Protein kinase B
Aged
Janus Kinases
Chromosome Aberrations
Gene Expression Profiling
medicine.disease
ta3122
High-Throughput Screening Assays
Gene expression profiling
Thiazoles
030104 developmental biology
Drug Resistance
Neoplasm
Leukemia
Prolymphocytic
T-Cell
Histone deacetylase
Drug Screening Assays
Antitumor
Ex vivo
Zdroj: Leukemia
ISSN: 0887-6924
DOI: 10.1038/leu.2017.252
Popis: T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive neoplasm of mature T-cells with an urgent need for rationally designed therapies to address its notoriously chemo-refractory behavior. The median survival of T-PLL patients is
Databáze: OpenAIRE
Externí odkaz: